反応式
[CH3:1][O:2][C:3]1[N:8]=[CH:7][C:6]([NH2:9])=[CH:5][N:4]=1.F[C:11]1[C:16]([C:17]2[N:22]=[C:21]([CH3:23])[N:20]=[C:19]([N:24](CC3C=CC(OC)=CC=3)CC3C=CC(OC)=CC=3)[N:18]=2)=[CH:15][C:14]([CH2:43][N:44]2[CH2:49][CH2:48][N:47]([S:50]([CH3:53])(=[O:52])=[O:51])[CH2:46][C@@H:45]2[CH3:54])=[CH:13][N:12]=1>>[CH3:1][O:2][C:3]1[N:8]=[CH:7][C:6]([NH:9][C:11]2[C:16]([C:17]3[N:22]=[C:21]([CH3:23])[N:20]=[C:19]([NH2:24])[N:18]=3)=[CH:15][C:14]([CH2:43][N:44]3[CH2:49][CH2:48][N:47]([S:50]([CH3:53])(=[O:51])=[O:52])[CH2:46][C@@H:45]3[CH3:54])=[CH:13][N:12]=2)=[CH:5][N:4]=1参加物
反応物 2
生成物 1
実験手順
The title compound was prepared from 2-methoxypyrimidin-5-amine (Aces Pharma, Inc.) and (S)-4-(2-fluoro-5-((2-methyl-4-(methylsulfonyl)piperazin-1-yl)methyl)pyridin-3-yl)-N,N-bis(4-methoxybenzyl)-6-methyl-1,3,5-triazin-2-amine (preparation similar as reported in Example 316, Steps 1 to 2; from (S)-tert-butyl 3-methylpiperazine-1-carboxylate (Sigma Aldrich, Inc.)) via similar steps as previously described in Example 316 and isolated as a yellow solid. m/z (ESI, +ve ion) 501 (M+H)+. 1H NMR (400 MHz, d6-DMSO) δ 11.77 (s, 1H) 9.03 (s, 2H) 8.71 (d, J=1.96 Hz, 1H) 8.24 (d, J=2.15 Hz, 1H) 7.90 (br. s., 1H) 7.74 (br. s., 1H) 3.91 (s, 3H) 3.24 (d, J=13.50 Hz, 2H) 2.86-2.96 (m, 1H) 2.85 (s, 3H) 2.55-2.79 (m, 4H) 2.44 (s, 3H) 2.11-2.37 (m, 2H) 1.16 (d, J=6.26 Hz, 3H).
後処理
- customisolated as a yellow solid
出典と根拠
- ORDレコード
- ord-0a721e20c6f5492bb495cffe3e466f69
- 出典データセット
- uspto-grants-2013_01
- 特許番号
- US08362241B2
関連ノート
読み込み中…